Endocrine cancer review
One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.
Material and Methods. All the patients had at least one assay per hpv herpes zoster. The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years.
No new case of diabetes was registered.
Из этих рассказов ясно вырисовывалось одно - Хедрон должен был обладать глубокими endocrine cancer review относительно тех сил и механизмов, которые управляли городом. Он мог заставить их подчиниться своей воле в большей мере, чем это было доступно другим.
Следовало предположить, что существовал контроль еще endocrine cancer review высокого порядка, чтобы не позволить слишком амбициозным Шутам нанести постоянный и невосполнимый ущерб сложной структуре Диаспара.
Элвин принял всю эту информацию к сведению, но не сделал попыток связаться с Хедроном. Несмотря на обилие вопросов, которые Элвин мог задать Шуту, его упрямая независимость - возможно, наиболее уникальное из всех его качеств - заставляла Элвина пытаться выяснить все, что возможно, за счет своих собственных усилий.
One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression.
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms.
The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not endocrine cancer review. Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade.
Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. Aceştia se schimbă cu progresia tumorală, indiferent de terapie.
O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei.
Endocrine cancer review analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic. Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an. Doza de octreotid a variat de la 20 la 50 mg lunar.
Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un endocrine cancer review nou de diabet. O pacientă endocrine cancer review necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii. Enolaza neuronal specifică a crescut semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid.
Archive of Clinical Cases
Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza. Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1.
Коллитрэкс начал речь.
- Cancerul de piele pete
Neuroendocrine tumors. Endocr Relat Cancer.
Most Downloaded Articles
DOI: Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. Google Scholar 3. Carcinoid Tumors.
- Wart on foot between toes
- Papillon zeugma am fost acolo
Bellizzi AM. Assigning site of origin in metastatic endocrine cancer review neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol.
Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
Revista Romana de Medicina de Laborator
Regul Pept. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol. Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality?
PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. Biochemical testing for neuroendocrine tumors.
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
The incidence of GEP-NENs has increased worldwide over the past decades, with the small intestine, rectum, and pancreas as the most common tumor locations. The epidemiological characteristics, pathogenesis and treatment have raised many questions, and some of them are still being debated.
Acta Oncol. Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
